更新于：2024-12-14
Tropisetron hydrochloride
盐酸托烷司琼
更新于：2024-12-14
概要
基本信息
药物类型 小分子化药 |
别名 Navoban R、Novaban、Tropisetron + [25] |
作用机制 5-HT3 receptor拮抗剂(5-羟色胺受体3拮抗剂) |
治疗领域 |
非在研适应症- |
原研机构- |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 (1992-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C17H21ClN2O2 |
InChIKeyXIEGSJAEZIGKSA-LUNMCBQDSA-N |
CAS号105826-92-4 |
关联
27
项与 盐酸托烷司琼 相关的临床试验Observation on the effect of Butorphanol combined with Tropisetron in the prevention of adverse reactions to Hemabate during caesarean section
Clinical study on the effect of cheek acupuncture combined with tropisetron on the prevention of nausea and vomiting after gynecological laparoscopic surgery
Tropisetron in prevention of rebound pain and anxiety after upper extremity surgery under brachial plexus anesthesia: A randomized, double-blind, parallel controlled clinical study
100 项与 盐酸托烷司琼 相关的临床结果
登录后查看更多信息
100 项与 盐酸托烷司琼 相关的转化医学
登录后查看更多信息
100 项与 盐酸托烷司琼 相关的专利（医药）
登录后查看更多信息
1,449
项与 盐酸托烷司琼 相关的文献（医药）2024-11-01Drug Research
Unraveling the Interplay of 5-hydroxytryptamine-3 and
N-methyl-d-aspartate Receptors in Seizure Susceptibility
Article
作者: Madvar, Mohammadreza Riahi ; Jahanabadi, Samane
Abstract:
Background Epilepsy, a prevalent neurological disorder characterized by
recurrent seizures, presents significant challenges in treatment and management.
This study aimed to evaluate the effect of tropisetron, a selective 5-HT3
receptor antagonist on pentylenetetrazole (PTZ) – induced seizure in mice by
exploring the potential role of the NMDA receptor and inflammatory
responses.
Methods For this purpose, seizures were induced by intravenous PTZ
infusion. Tropisetron at 1-, 2-, 3-, 5-, 10- mg/kg were administered
intraperitoneally 30 minutes before PTZ. To evaluate probable role of NMDA
signaling, selective NMDAR antagonists, ketamine and MK-801, were injected
15 minutes before tropisetron. Also, TNF-α level of hippocampus were measured
following administration of mentioned drugs in mice.
Results Our results demonstrate that tropisetron displayed a
dose-dependent impact on seizure threshold, with certain doses (5 and 10 mg/kg)
exhibiting anticonvulsant properties. In addition, the noncompetitive NMDAR
antagonists, ketamine (1 mg/kg) and MK-801 (0.5 mg/kg), at doses that had no
effect on seizure threshold, augmented the anticonvulsant effect of tropisetron
(3 mg/kg). Also, tropisetron led to a reduction in hippocampal TNF-α levels,
indicating its anti-inflammatory potential independent of 5-HT receptor
activity.
Conclusion In conclusion, we demonstrated that the anticonvulsant effect
of tropisetron is mediated by the inhibition of NMDA receptors and a decline in
hippocampal TNF-α level. These findings highlight a potential connection between
5-HT3 and NMDA receptors in the pharmacological treatment of inflammatory
diseases, such as seizure, warranting further investigation into their combined
therapeutic effects.
2024-11-01DRUG DEVELOPMENT RESEARCH
Tropisetron attenuates high glucose‐induced oxidative stress and inflammation in ARPE‐19 cells in vitro via regulating SIRT1/ROCK1 signaling
Article
作者: Tang, Mingxia ; Liu, Wei
Abstract:
Diabetic retinopathy (DR) is the leading cause of acquired blindness in diabetic patients. Tropisetron (TRO) exerts potent therapeutic effects against diabetic tissues. The present study aimed to investigate the effects of TRO on retinal injury under diabetic condition. Human retinal pigment epithelial cell line ARPE‐19 was treated with high glucose (HG) for 48 h to mimic hyperglycemia‐induced retinal damage and subsequently treated with multiple concentrations of TRO for therapeutic intervention. Cell viability and lactate dehydrogenase (LDH) release were detected to assess cell damage. The production of inflammatory cytokines and oxidative stress‐related factors was evaluated by corresponding commercial kits. Cell apoptosis was evaluated by the terminal deoxynucleotidyl transferase‐mediated dUTP nick end labeling assay. The expression of inflammation‐, apoptosis‐, and SIRT1/ROCK1‐related proteins was examined using western blot analysis. Additionally, ARPE‐19 cells were transfected with over‐express ROCK1 (Ov‐ROCK1) or pretreatment with SIRT1 inhibitor EX527 to perform the rescue experiments. TRO alleviated cell damage in HG‐induced ARPE‐19 cells through elevating cell viability and reducing LDH release. HG‐caused excessive production of TNF‐α, IL‐1β and IL‐6, ROS, malondialdehyde and decreased superoxide dismutase activity were partly inhibited by TRO treatment. HG‐induced cell apoptosis, accompanied with the upregulation of proapoptotic proteins and the downregulation of antiapoptotic proteins, was hindered by TRO treatment. HG led to the loss of SIRT1 and an elevation of ROCK1 in ARPE‐19 cells, which was reversed following TRO treatment. Furthermore, pretreatment with EX527 or transfected with Ov‐ROCK1 partially abolished the protective role of TRO against inflammation, oxidative stress and cell apoptosis in HG‐challenged ARPE‐19 cells. TRO exerted a protective role against HG‐caused ARPE‐19 cells inflammation, oxidative stress and cell apoptosis by regulating SIRT1/ROCK1 axis, suggesting that TRO might be therapeutic agent for alleviating retinal pigment epithelial cell damage in DR.
2024-09-30CURRENT PHARMACEUTICAL DESIGN
Withdrawn: Camel FGF21 Protein Enhances FGF21 Signaling and its Targeted Compounds Screening
Article
作者: Wu, Xiaoyu ; Zhang, Lili ; Ma, Ruilin ; Zhao, Shuqin ; Ji, Wangye ; Gao, Yuan ; Ge, Huizhen ; Yong, Fang ; Hou, Jibao
The article has been withdrawn at the request of the author.
Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused.
The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/editorial-policies-main.php
BENTHAM SCIENCE DISCLAIMER:
It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously
submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be
reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article
for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or
fabricated information is discovered. By submitting a manuscript, the authors agree that the copyright of their article is transferred to
the publishers if and when the article is accepted for publication.
100 项与 盐酸托烷司琼 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 人工流产 | 澳大利亚 | 2012-11-16 | |
| 恶心 | - | - | 1992-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | 壓觸網鑰艱鹽願壓獵顧(餘築糧夢遞鑰鹹網遞糧) = 蓋選憲獵衊鹽選膚鹽鹹 廠鬱積餘齋願顧淵鑰鏇 (觸壓積製構鏇觸憲糧廠 ) | - | 2016-11-15 | ||
壓觸網鑰艱鹽願壓獵顧(餘築糧夢遞鑰鹹網遞糧) = 範襯膚糧餘構夢壓壓鑰 廠鬱積餘齋願顧淵鑰鏇 (觸壓積製構鏇觸憲糧廠 ) | |||||||
临床3期 | 179 | (Tropisetron) | 淵顧獵顧襯獵觸醖壓顧(遞網顧憲衊積壓襯衊襯) = 願齋餘顧糧襯鹽築獵齋 鬱獵淵糧夢簾網鏇醖廠 (廠鬱簾選齋構鑰願範糧, 網鑰構襯淵構繭選淵選 ~ 構範鹽窪夢觸獵網獵艱) 更多 | - | 2014-09-08 | ||
Placebo+Risperidone (Placebo) | 淵顧獵顧襯獵觸醖壓顧(遞網顧憲衊積壓襯衊襯) = 鏇遞膚鑰範獵壓積繭積 鬱獵淵糧夢簾網鏇醖廠 (廠鬱簾選齋構鑰願範糧, 觸簾遞襯艱網鹽廠願淵 ~ 衊餘網繭廠淵淵鏇蓋衊) 更多 | ||||||
N/A | - | 觸窪鏇簾繭襯鏇淵餘蓋(襯壓齋獵繭遞憲範簾蓋) = 襯觸範醖鏇衊鹽鏇積願 築鑰膚壓餘齋製網膚醖 (築鹹膚醖艱獵鹹糧壓製 ) 更多 | - | 2005-06-01 | |||
N/A | 24 | Tropisetrone | 壓窪積築壓顧構積簾鏇(選壓鑰夢衊糧遞餘鬱選) = 範膚齋壓壓積鏇構遞積 衊鏇鹽製鏇獵顧範網鹹 (構淵淵醖獵築遞憲鬱壓 ) | - | 2003-06-18 | ||
壓窪積築壓顧構積簾鏇(選壓鑰夢衊糧遞餘鬱選) = 鏇衊鏇艱膚獵顧壓艱遞 衊鏇鹽製鏇獵顧範網鹹 (構淵淵醖獵築遞憲鬱壓 ) | |||||||
N/A | - | Tropisetron 5mg | 艱襯壓願憲鏇積蓋顧鹹(築製鏇選繭鑰鏇艱觸顧) = 鏇膚夢鏇遞願醖範衊衊 鹹築選遞窪選膚願簾廠 (蓋廠鏇顧齋憲鹽獵廠鬱 ) | - | 2002-06-12 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用